Aptevo Therapeutics Inc. key statistics and ratios
In fiscal 2022, Aptevo Therapeutics Inc. had return on equity of 83.7%, an operating margin of -919.7%, debt equal to 22.3% of equity and a current ratio of 3.15. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | 51.4% | 38.5% | — | — | — |
| Operating margin | −181.8% | <−999% | −368.1% | −224.0% | −126.3% | −638.1% | −174.1% | −919.7% |
| Net margin | −176.5% | <−999% | 47.6% | −232.8% | −124.7% | −411.9% | −231.5% | 257.8% |
| Free-cash-flow margin | −149.7% | −394.3% | −293.2% | −227.2% | −131.2% | −682.4% | −182.2% | −676.0% |
| Return on equity | −66.9% | −161.5% | 10.5% | −95.5% | −191.5% | −124.8% | — | 83.7% |
| Return on assets | −46.4% | −102.4% | 6.7% | −58.2% | −66.9% | −33.2% | −51.7% | 17.7% |
| Asset turnover | 0.26 | 0.09 | 0.14 | 0.25 | 0.54 | 0.08 | 0.22 | 0.07 |
| Current ratio | 1.76 | 3.65 | 5.14 | 2.76 | 0.78 | 3.25 | 1.51 | 3.15 |
| Debt to equity | 0.0% | 36.4% | 23.2% | 63.4% | 332.9% | 170.1% | >999% | 22.3% |
| R&D as % of revenue | 103.3% | 291.6% | 198.0% | 153.4% | 76.4% | 414.3% | 154.5% | 574.2% |
| SG&A as % of revenue | 128.1% | 362.1% | 235.9% | 122.0% | 78.1% | — | — | — |
| Capital spending as % of revenue | 4.5% | 25.2% | 9.6% | 4.2% | 0.5% | 2.0% | 5.8% | 0.9% |
| Free cash flow ÷ net income | — | — | −616.3% | — | — | — | — | −262.3% |
| Quarter | 2021 Q1Mar 2021 | 2021 Q2Jun 2021 | 2021 Q3Sept 2021 | 2021 Q4Dec 2021 | 2022 Q1Mar 2022 | 2022 Q2Jun 2022 | 2022 Q3Sept 2022 | 2022 Q4Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | −284.5% | −184.0% | −153.4% | −110.2% | −180.2% | — | — | — |
| Net margin | −299.7% | −255.0% | −226.0% | −171.1% | −247.2% | — | — | — |
| Free-cash-flow margin | −317.8% | −175.0% | −169.7% | −109.1% | — | — | — | — |
| Current ratio | 2.14 | 2.13 | 1.82 | 1.51 | 1.75 | 4.48 | 3.16 | 3.15 |
| Debt to equity | 96.8% | 76.8% | 153.1% | >999% | — | 8.7% | 24.8% | 19.2% |
| R&D as % of revenue | 221.5% | 151.8% | 141.1% | 124.0% | 156.3% | — | — | — |
Moat
Weak moat
How hard Aptevo Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -90.7% of total assets over 10 years.
- Durability 10 / 20
Operating margin has been a median -224.0%; its worst year was -919.7%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 5 years, at a median -188.1% of revenue.
- Discipline 0 / 20
The diluted share count rose 195130.8% over five years; stock-based pay has been a median 13.1% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
Compare with peers
More: Biotechnology stocks compared, Health Care sector, rankings of US companies